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Abstract: Reactive oxygen species (ROS) play important roles in cell signaling and homeostasis.
However, an abnormally high level of ROS is toxic, and is implicated in a number of diseases. Positron
emission tomography (PET) imaging of ROS can assist in the detection of these diseases. For the
purpose of clinical translation of [18F]6-(4-((1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-
5-methyl-5,6-dihydrophenanthridine-3,8-diamine ([18F]DHMT), a promising ROS PET radiotracer,
we first manually optimized the large-scale radiosynthesis conditions and then implemented them in
an automated synthesis module. Our manual synthesis procedure afforded [18F]DHMT in 120 min
with overall radiochemical yield (RCY) of 31.6% ± 9.3% (n = 2, decay-uncorrected) and specific
activity of 426 ± 272 GBq/µmol (n = 2). Fully automated radiosynthesis of [18F]DHMT was achieved
within 77 min with overall isolated RCY of 6.9% ± 2.8% (n = 7, decay-uncorrected) and specific
activity of 155 ± 153 GBq/µmol (n = 7) at the end of synthesis. This study is the first demonstration
of producing 2-[18F]fluoroethyl azide by an automated module, which can be used for a variety of
PET tracers through click chemistry. It is also the first time that [18F]DHMT was successfully tested
for PET imaging in a healthy beagle dog.
Keywords: PET; reactive oxygen species; in vivo imaging; automation; 2-[18F]fluoroethyl azide;
translational study
1. Introduction
Reactive oxygen species (ROS) are chemically reactive species, such as singlet oxygen, hydrogen
peroxide, hydroxyl radicals and superoxide. ROS are involved in cell signaling which is important
in the maintenance of cell homeostasis [1]. However, a sustained high level of ROS is detrimental
and believed to be associated with diseases such as cancer [2,3], ischemic heart disease [4] and
chemotherapy-induced cardiotoxicity [5]. Development of ROS imaging probes will enable the
monitoring of ROS levels in vivo.
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As a non-invasive technique, positron emission tomography (PET) imaging of ROS can assist in
the detection of ROS levels in living subjects. There are several radiotracers reported for ROS imaging
with PET, such as [11C]ascorbic acid [6], peroxy-caged-[18F]fluorodeoxy thymidine-1 (PC-FLT-1) [7],
and the dihydroquinoline derivatives [11C]DHQ1 [8] and [18F]DHMT [9]. Among them, [18F]DHMT,
[11C]DHQ1, and [11C]ascorbic acid have been tested in rodents. However, the short half-life (20 min)
of carbon-11 limits the [11C]-labeled tracers from widespread clinical applications, as they require
an on-site cyclotron for production. Alternately, [18F]DHMT is more advantageous, not only in that
the longer half-life of fluorine-18 permits off-site production and transportation to multiple clinics, but
also in that it can be selectively oxidized by superoxide and trapped in the cell irreversibly [9].
The usefulness of [18F]DHMT as an ROS imaging agent has been shown in the detection of
doxorubicin-induced cardiotoxicity in a rodent model [9]. However, in the study only small-scale
production of [18F]DHMT was reported (starting from 1.9 GBq of [18F]fluoride). It is challenging to
scale up the production to make a large batch for multiple clinical doses, as the product is sensitive to
radiolysis. Following the reported method, oxidation of the product was observed during the HPLC
purification and formulation processes. In order to translate it to clinical investigations, we developed
a robust and fully automated radiosynthesis of [18F]DHMT, which consistently yielded the product in
large quantity, and with quality suitable for human use. PET imaging of the heart of a healthy beagle
dog was also performed using [18F]DHMT. Dogs were chosen because they have been shown to be the
ideal large animal for modeling human cardiotoxicity with similar chemotherapy doses [10–12].
2. Results
2.1. Manual Radiosynthesis under Optimized Conditions
[18F]DHMT was synthesized manually in high yield via a two-step, two-pot reaction sequence
modified from the previously described method (Scheme 1) [9]. The first step was to prepare
2-[18F]fluoroethyl azide ([18F]2) from 2-azidoethyl tosylate (1). In the manual synthesis, consistently
high isolated radiochemical yield (RCY) of 79% ± 8% (n = 3, decay corrected) was obtained for [18F]2,
using 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (Kryptofix 2.2.2 or K2.2.2, 5.6 mg),
potassium carbonate (K2CO3, 1 mg), and anhydrous [18F]fluoride at 90 ◦C for 10 min. It was purified
by passing through two stacked SepPak cartridges, eluted off with N,N-dimethylformamide (DMF,
0.5 mL), and used for the second step reaction.
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Scheme 1. Reaction scheme for [18F]DHMT radiosynthesis. 
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the final product. No formation of byproducts was observed. The crude mixture was purified by 
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Subsequently, Cu(I)-catalyzed click chemistry was used to construct the triazole unit of [18F]DHMT
([18F]5). Using a commercially available Cu(I)-stabilizing ligand, tris[(1-benzyl-1H-1,2,3-triazol-4-yl)
methyl]amine (TBTA), the click reaction proceeded smoothly in a solvent mixture of ethanol,
ammonium acetate buffer (pH = 7), and DMF (6/9/51, v/v/v), with 88% ± 3% (decay corrected, n = 2)
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conversion to the final product. No formation of byproducts was observed. The crude mixture was
purified by semi-preparative high-performance liquid chromatography (HPLC, Figure 1a, retention
time for [18F]5: 16–18 min), and formulated for intravenous injection.
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Figure 1. Semi-preparative radio-HPLC chromatograms for purification of [18F]DHMT ([18F]5).
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2.2. Automated Radiosynthesis of [18F]DHMT
Fully automated radiosynthesis of [18F]DHMT with [18F]2 was achieved within 77 min. The overall
isolated RCY of [18F]DHMT was 6.9% ± 2.8% (decay-uncorrected, n = 7), starting from 63 to 107 GBq
of [18F]fluoride. Specific activity was 155 ± 153 GBq/µmol (n = 7) at the end of synthesis.
2.3. Quality Control and Stability Tests of [18F]DHMT
Quality control results from large-sc le productions of [18F]DHMT are shown in able 1.
The product solution was clear a d colorless, with pH of about 7 (n = 9). The radiochemical purit of
[18F]DHMT was 96.3% ± 1.9% (n = 9). The radionuclide i entity was determined by measuring the
radioactive decay half-life of [18F]DHMT, which was 110.2 ± 3.9 min (n = 9) and c nsistent with the
half-life of fluorine-18. One typical production batch of [18F]DHMT was checked with all the quality
control tests required for human use. For this production, levels of residual solvents and K2.2.2 were
below the levels set by the US FDA and results for other tests all met the specifications for human use.
Table 1. Quality control results of [18F]DHMT.
Test Release Criteria for Human Use Result
Visual inspectio (n = 9) Clear, colorless Clear, colorless
Solution pH (n = 9) 4.5–8.5 7
Residual solvent test (n = 1) MeCN < 0.41 mg/mL, DMF < 0.88 mg/mL Pass
K2.2.2 test (n = 1) <0.05 mg/mL Pass
Endotoxin test (n = 1) <17.5 EU/mL <5 EU/mL
Sterile filter integrity test (n = 1) Bubble point pressure > 50 psi Pass
Sterility test (n = 1) No bacterial growth Pass
Radiochemical purity (n = 9) >90% 96.3% 1.9%
Radionuclide identity (n = 9) Measured t1/2 between 98.8 to 128.8 min 110.2 ± 3.5 min
The identity of [18F]DHMT was confirmed by co-injection of the final radioactive product with
the non-radioactive reference standard, and co-elution of the UV and radioactive peaks on the HPLC
chromatogram (Figure 2). Moreover, stability test for [18F]DHMT produced using either the manual or
automated method indicated that the radiochemical purity was maintained above 90% at 6 h after the
end of synthesis.
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2.4. Comparison of Three Methods for Radiosynthesis of [18F]DHMT
Table 2 shows s mma y of the three me hods for [18F]DHMT radiosy thesis. Our modified
manual synthesis procedure afforded [18F]DHMT in a total synthesis time of about 120 min, with
overall RCY of 31.6% ± 9.3% (n = 2, decay-uncorrected, based on starting [18F]fluoride activity of
100–101 GBq) and specific activity of 426± 272 GBq/µmol (n = 2) at the end of synthesis. For automated
radiosynthesis, [18F]DHMT was prepared in a total synthesis time of about 77 min. More than 4.44 GBq
of the final product was obtained, with specific activity of 155 ± 153 GBq/µmol (n = 7) at the end of
synthesis. We found a decrease in RCY (6.9%± 2.8%, n = 7, decay-uncorrected) for automated sy thesis
compared with manual synthesis. The se i-prep rative HPLC chromatogram for the purification
of [18F]DHMT in an automated synthesis (Figure 1b) also confirmed that ther was more [18F]2
left unreacted when compared with manual synthesis. For manual and automated radiosynthesis,
[18F]DHMT was produced with radiochemical purity of 93.9% ± 0.6% (n = 2) and 96.9% ± 1.7%
(n = 7), respectively.
Tabl 2. Comparison of three methods for radiosynthesis of [18F]DHMT.





Literature [9] 42.8 90–100 13–24 120
Manual (n = 2) 31.6 ± 9.3 93.9 ± 0.6 426 ± 272 ~120
Automated (n = 7) 6.9 ± 2.8 96.9 ± 1.7 155 ± 153 ~77
* Decay-uncorrected RCY calculated based on the isolated product and starting [18F]fluoride.
2.5. Animal Imaging
Shown in Figure 3 are transverse, coronal and sagittal slices of PET images obtained from
60 to 90 min after intravenous injection of [18F]DHMT in a beagle dog. The images exhibited high
myocardial-to-background ratios, especially in the left ventricle. The standardized uptake value ratio
was 2.3 between the left ventricle and the blood pool, and 0.14 between the left ventricle and the liver.
The right ventricle and papillary muscle were also clearly visible.
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We have carried out multiple imaging studies with high specific activity [18F]DHMT, with injection
mass of 1.05 ± 0.84 µg (n = 9). No adverse effects from the radiotracer were observed. Data analyses
for PET imaging of healthy and diseased beagle dog models with [18F]DHMT are underway and the
results will be published elsewhere.
3. Discussion
The ROS radiotracer [18F]DHMT was synthesized manually in high yield and with high specific
activity via a two-step, two-pot reaction sequence. In our hands, the click reaction using copper(II)
sulfate (CuSO4) and sodium ascorbate as reported in the literature failed to yield the desired product
consistently. In addition, oxidation of the product during HPLC purification and post-processing was
also observed. We optimized the synthesis of [18F]DHMT for a more consistent and reliable production,
and successfully adapted it to a commercially available automated synthesis module.
The first step concerned the preparation of 2-[18F]fluoroethyl azide ([18F]2). We used a recently
developed solid-phase extraction method instead of vacuum distillation to purify [18F]2. This solid-phase
extraction method used two connected SepPak cartridges in series. [18F]2 was selectively trapped
on the second cartridge, and eluted out for the second step reaction. The isolated yield of [18F]2 was
similar to that reported (ca. 80%). This purification method is simple and reproducible, and thus
particularly suitable for implementation in the automated production of 18F-labeled PET probes using
[18F]2 [13].
For the click reaction, it failed to yield the desired product consistently when we employed CuSO4
and sodium ascorbate as reported in the literature, probably due to the facile disproportionation of
Cu(I) in aqueous solution to Cu(II) and its colloid, followed by oxidation of the product by Cu(II).
In Cu-catalyzed alkyne-azide click reactions, Cu(I)-stabilizing ligands are preferred for their high
efficiency during synthesis. TBTA is a commonly used and commercially available Cu(I)-stabilizing
ligand. We used a cocktail of TBTA, CuSO4, N,N-di-isopropylethylamine (DIEA), and sodium ascorbate
in the subsequent click reaction, which resulted in a highly efficient conversion and minimal formation
of the oxidized byproduct.
ROS are generated by the ionizing radiation of radiolabeled products. [18F]DHMT is susceptible
to ROS and radiolysis, which can irreversibly oxidize it to its inactive form. Therefore, it is important
to reduce or eliminate radiolysis, which is challenging for large-scale production. In the previously
published work, a starting radioactivity of 1.9 GBq [18F]fluoride was used and the involvement of
radiolysis was not obvious. We found significant radiolysis of the product when we scaled up the
production with large amount of starting [18F]fluoride (more than 63 GBq). Different HPLC purification
conditions were investigated to minimize oxidation and radiolysis of the final product during the
process, and to make the radiosynthesis of [18F]DHMT more robust and reliable for routine large-scale
production. We found that addition of ascorbic acid [14,15] to the semi-preparative HPLC solvent and
formulation solution prevented radiolysis during purification and formulation of the product.
We implemented the modified steps in two runs of [18F]DHMT using manual operations.
The isolated yields of [18F]DHMT after semi-preparative HPLC and solid-phase extraction were
slightly lower than those reported previously (40.9% and 22.3% vs. 42.8%). The radiochemical purity
of the final product was 93.5% and 94.3%, respectively (Table 2).
We then translated the two-pot, two-step synthesis of [18F]DHMT to a fully automated module.
All steps, including the initial receiving, eluting and drying of [18F]fluoride from cyclotron target
water, direct 18F-fluorination to form [18F]2, SepPak purification of [18F]2, [18F]DHMT formation
by click reaction and, finally, preparative HPLC for product isolation, were successfully adapted to
the TRACERLab® FXN Pro module (GE Healthcare, Milwaukee, WI, USA). Manual radiosynthesis
of [18F]2 has been reported previously [16,17]. However, the isolation method for [18F]2 involved
distillation, which cannot be readily implemented in automated modules. Only one paper has reported
a two-step, one-pot method for automated production using [18F]2. However, this two-step one-pot
approach requires a large amount of alkyne precursors [18]. As mentioned above, we used a recently
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developed solid-phase extraction method to isolate [18F]2, which is amenable to adaptation in an
automated process. To implement this method, we added a second SepPak between VX1 and VX3
in the module as indicated in Figure 4. To the best of our knowledge, this is the first report of
implementing this solid-phase extraction method in an automated module for the purification and
isolation of [18F]2 for use in subsequent click chemistry. Our method can be widely applied to other
automated radiosynthesis via the alkyne-azide click reaction with [18F]2.
Quality control results revealed that the [18F]DHMT product met all the current requirements
of a radiotracer for human use (Table 1). Our methods produced [18F]DHMT in consistently high
radiochemical purity, and with specific activity higher than that reported in the literature (Table 2).
The final product from both manual and automated synthesis was stable, maintaining a radiochemical
purity of more than 95% after 6 h from the end of synthesis. We found a high degree of variability
in the specific activity of the final product. The water in the [18F]fluoride transfer line appeared to
be the main factor for this variability. When the transfer line from the cyclotron to the module was
cleaned and dried immediately before the radiosynthesis, a high specific activity product was obtained.
When it was not cleaned and dried, a lower specific activity resulted.
A decrease in the RCY of [18F]DHMT was found when transitioning from manual to automated
synthesis (6.9% ± 2.8%, n = 7, Table 2). The possible explanation for this is that a larger volume of
DMF was used to elute [18F]2 from the SepPak, which diluted the concentrations of the reactants in
the second reactor, resulting in a less efficient click reaction. Nonetheless, the quantity of isolated
[18F]DHMT from the automated method was sufficient for clinical applications.
Previously, [18F]DHMT has been validated for ROS detection through in vitro assays and in vivo
imaging studies in rodents. In this study, we further applied this tracer to a large animal model. The dog
images showed high myocardial-to–blood pool ratios with reasonable liver uptake. These ratios are
similar to those obtained from previous studies in mice [9]. Our probe is an analog of dihydroethidium,
which has been widely used for fluorescence-based detection of superoxide. Therefore, [18F]DHMT
may have properties similar to those of dihydroethidium, such as oxidation by heme proteins.
This could be the major route of probe oxidation in cardiac cells expressing high levels of heme
proteins [19]. Thus, the baseline radiotracer uptake in the dog heart may be attributed to its oxidation by
heme proteins. However, [18F]DHMT can still be used for detecting doxorubicin-induced cardiotoxicity,
where ROS levels increase significantly in the heart [20].
Another point worth noting is that, as an analog of ethidium bromide, DHMT may display similar
toxicity as ethidium bromide. Nonetheless, PET imaging with [18F]DHMT involves microdosing,
with trace amount of injected mass, and toxicological effects from the radiotracer are not expected.
As a matter of fact, we have carried out multiple imaging experiments in beagle dogs with injected
mass dose of 1.05 ± 0.84 µg (n = 9) and no adverse effects were observed.
In summary, we have optimized the large-scale radiosynthesis of [18F]DHMT, transferred it to
a commercially available automated synthesis module, and demonstrated the feasibility of using
[18F]DHMT for PET imaging of the heart in a canine model. Future studies with this radiotracer will
include its use in the detection of doxorubicin-induced cardiotoxicity.
4. Materials and Methods
4.1. General
All chemicals used were at least of analytical grade and obtained from commercial sources,
unless otherwise specified. The reference standard and respective precursor for [18F]DHMT were
synthesized following published procedures [9]. [18F]Fluoride was produced via the 18O(p, n) 18F
nuclear reaction by irradiation of [18O]H2O (Huayi Isotopes, Toronto, ON, Canada) in a GE PETtrace
cyclotron (GE Medical Systems, Uppsala, Sweden) with 16.5 MeV proton beam. Anion exchange
Chromafix cartridges (PS-HCO3) for [18F]fluoride trapping were purchased from Macherey-Nagel
Molecules 2016, 21, 1696 7 of 11
(Dueringen, Germany). Solid-phase extraction cartridges (SepPak® Light C18, SepPak® Plus tC18 and
Oasis® Plus HLB) were purchased from Waters Associates (Milford, MA, USA).
The semi-preparative HPLC system was composed of a Shimadzu LC-20A pump (Shimadzu
Corp., Kyoto, Japan) equipped with a Knauer K200 UV detector (Knauer Wissenschaftliche Geräte
GmbH, Berlin, Germany), set at 254 nm, and a Bioscan radioactivity detector with Phenomenex
Luna C18 (2) column (10 µm, 250 × 10 mm). Semi-preparative HPLC mobile phase was made of
35% MeCN and 65% 0.1 M ammonium formate with ascorbic acid (0.3 g/L). The flow rate was
at 5 mL/min. The analytical HPLC system included a Shimadzu LC-20A pump equipped with
a SPD-M20A Photodiode Array (PDA) detector (Shimadzu Corp., Kyoto, Japan) or a SPD-20A UV/Vis
detector set at 234 nm, a Bioscan flow-through radioactivity detector, and a Genesis C18 column (4 µm,
250 × 4.6 mm). Analytical HPLC mobile phase was 33% MeCN and 67% 0.1 M ammonium formate
with 0.5% acetic acid (pH 4.2) at a flow rate of 2 mL/min.
4.2. Radiochemistry
4.2.1. Manual Radiolabeling of [18F]DHMT under Optimized Reaction Conditions
Deprotection of 3 to Prepare Precursor 4
Under an argon atmosphere di-tert-butyl (5-methyl-6-(4-(prop-2-yn-1-yloxy)phenyl)-5,6-
dihydrophenanthridine-3,8-diyl)dicarbamate (3, 2 mg, 3.51 µmol) in CH2Cl2 (100 µL) was added
to a solution of ascorbic acid (1 mg, 5.68 µmol) in TFA (100 µL, 1.3 mmol) and deionized (DI) water
(10 µL) in a 2 mL borosilicate glass V-vial wrapped with aluminum foil. After mixing, the reaction was
allowed to proceed at ambient temperature for 15 min, with brief vortexing every 5 min. The solvents
were dried under vacuum or argon stream at ambient temperature to afford 4 as a pale yellow solid,
which was then dissolved with a solution of DIEA in DMF (200 µL, DIEA/DMF = 1/10, v/v) to form
a pink solution for use in the click reaction with [18F]2.
Preparation of Cu(I) Catalyst
A solution of CuSO4-TBTA was prepared by mixing CuSO4 (0.4 M in 0.1 M ammonium acetate,
pH = 7, 30 µL) and TBTA (0.3 M in DMF, 40 µL). The Cu(I) catalyst was prepared by mixing freshly
dissolved sodium ascorbate (18 mg, 91 µmol) in water/ethanol (1:1, v/v, 120 µL) with the above
CuSO4-TBTA solution to form a brown slurry which turned to a colorless solution upon mixing at
ambient temperature.
Preparation of 2-[18F]fluoroethyl azide ([18F]2)
Preparation of [18F]2 followed the literature procedures [13]. Cyclotron-produced [18F]fluoride in
[18O]water was trapped on a PS-HCO3 anion-exchange cartridge pre-activated with ethanol (5 mL),
DI water (5 mL) and dried by air. The trapped [18F]fluoride (100–101 GBq) was eluted slowly with
1 mL of K2.2.2 (5.6 mg)/potassium carbonate (1 mg) solution in MeCN/water (70/30, v/v) into a 2 mL
borosilicate glass V-vial. The eluent was dried at 110 ◦C under argon, followed by azeotropic drying
with three 1.0 mL portions of anhydrous MeCN. Compound 1 (1.5–2.0 mg) in 0.2 mL anhydrous MeCN
was then added, followed by heating for 10 min at 90 ◦C with occasional shaking.
After cooling in ice-water (0 ◦C) for 1 min, the reaction mixture was diluted with DI water (10 mL)
and then passed through two stacked SepPak cartridges (a SepPak® Plus tC18 cartridge and an Oasis®
Plus HLB cartridge, both pre-activated by washing with 10 mL of EtOH followed by 10 mL of DI water).
The cartridges were rinsed with DI water (10 mL × 2). The Waters Oasis® Plus HLB cartridge was
taken off, dried with air, inverted, then eluted with DMF (3 × 0.5 mL) to collect [18F]2. The first portion
of 0.5 mL DMF was discarded, and the second portion of 0.5 mL DMF was used for the click reaction.
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Click Reaction to Form [18F]DHMT ([18F]5)
The solution of [18F]2 in DMF (0.5 mL) was added to a V-vial preloaded with a solution of 4
(3.51 µmol) in 200 µL of DIEA/DMF (1/10, v/v). The Cu(I) catalyst as prepared above was added
to the V-vial via a syringe and the reaction was carried out at ambient temperature for 10 min with
occasional shaking. The reaction mixture was then diluted with 1.2 mL of aqueous ascorbic acid
solution (0.57 mM), and injected onto the semi-preparative HPLC system for purification.
The product fraction at 16–18 min was collected, diluted with 50 mL of aqueous ascorbic acid
solution (0.57 mM), and loaded onto a SepPak® Light C18 cartridge pre-activated by washing with
10 mL of ethanol, and 10 mL of aqueous ascorbic acid solution (0.57 mM). The SepPak cartridge was
rinsed with 10 mL of aqueous ascorbic acid solution (0.57 mM). The product was then eluted off
with a solution of ascorbic acid (1 mg) in 1 mL of United States Pharmacopeia (USP) grade ethanol,
followed by 3 mL of USP grade sterile saline. The combined solution was then passed through a sterile
0.22 µm membrane filter (MILLEX-GV, Millipore, Millipore Corp., Billerica, MA, USA) into a vented
sterile dose vial pre-charged with 7 mL of USP grade sterile saline and 200 µL of USP grade sodium
bicarbonate solution (4.2%) to afford a formulated solution ready for intravenous administration.
4.2.2. Automated Radiosynthesis of [18F]DHMT
Reagent Loading
Radiosynthesis of [18F]DHMT was performed as a two-step, two-pot reaction in a custom-modified
dual-reactor TRACERLab® FXN Pro synthesis module (Figure 4). Reagent loading was as follows:
Vial 1: K2.2.2 (5.6 mg, 14.8 µmol) and K2CO3 (1 mg, 7.2 µmol) in 1 mL MeCN/H2O (7:3, v/v); Vial 2:
anhydrous MeCN (2 mL); Vial 3: compound 1 (2–4 mg) in MeCN (1 mL); Vial 4: DI water (5 mL); Vial 5:
DI water (18 mL); Vial 6: DMF (1 mL); Vial 7: compound 4 (2–4 mg) in 200 µL DIEA/DMF (1/10, v/v);
Vial 15: freshly prepared Cu(I) catalyst (the same amount and preparation method as that used in the
manual method); Vial 16: aqueous ascorbic acid solution (0.57 mM, 1.5 mL); Vial 18: aqueous ascorbic
acid solution (0.57 mM, 15 mL); Vial 43: aqueous ascorbic acid solution (0.57 mM, 15 mL); Vial 42:
ascorbic acid (1 mg) in USP grade ethanol (1 mL); Vial 41: USP grade saline (3 mL); Product vial: USP
grade saline (7 mL) with USP grade aqueous sodium bicarbonate solution (4.2%, 200 µL).
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Reaction Sequence
The optimized manual synthesis procedures for [18F]DHMT were transferred to an automated
module (Figure 4). Synthetic protocol started with the delivery of aqueous [18F]fluoride to the synthesis
module. [18F]fluoride was trapped on an 18F separation cartridge (F18 SEP) and eluted into the first
reactor (RV1, 12) with a solution of K2.2.2/K2CO3 (Vial 1). Azeotropic drying was performed under
reduced pressure at 70 ◦C for 10 min and a steady stream of argon. The addition of 1 mL MeCN from
Vial 2 and subsequent drying at 100 ◦C for 5 min was repeated twice. After drying, the solution of
compound 1 (Vial 3) was added into RV1 and heated at 85 ◦C for 15 min to form [18F]2. After cooling
down to 35 ◦C, 18 mL of DI water (Vial 5) was added and the content in RV1 was passed through the
two SepPak cartridges (14 and 13) sequentially, followed by washing with 5 mL of DI water (Vial 4).
The intermediate was eluted off SepPak 13 with 1 mL of DMF (Vial 6) into the second reactor (RV2, 15).
The precursor 4 in 0.2 mL of DIEA/DMF (Vial 7) was added and the reaction was carried out at ambient
temperature for 10 min. The crude reaction solution was transferred to Vial 16 and loaded onto the
semi-preparative HPLC system for purification.
The desired product fraction was collected in a round bottom flask (Vial 18), diluted with 15 mL
of aqueous ascorbic acid solution (0.57 mM), and passed through a SepPak® Light C18 cartridge
(17). The cartridge was washed with 10 mL of aqueous ascorbic acid solution (0.57 mM) from Vial 43.
The product was eluted off the SepPak with a solution of ascorbic acid (1 mg) in USP grade absolute
ethanol (1 mL) (Vial 42), followed by 3 mL of USP grade saline (Vial 41), into the Product Vial 19, which
was preloaded with 7 mL of USP grade saline and 200 µL of sodium bicarbonate aqueous solution
(4.2%). Terminal sterilization was performed by passing the final formulated solution in the Product
Vial through a 0.22 µm sterile membrane filter into a sterile Dose Vial (Vial 20).
4.3. Quality Control and Stability Test
Visual inspection of [18F]DHMT ([18F]5) was done behind a shielded L-block. The filter membrane
integrity test was done by a bubble pressure test. The filter was first rinsed by 10 mL of DI water and
then the inlet of the filter was attached to argon gas and the outlet of the filter was immersed in water.
The argon flow was slowly increased until there was continuous bubbling and the pressure reading
recorded as bubble pressure. Solution pH was measured by spotting the product solution onto a strip
of pH paper. Residual organic solvent analysis was conducted by gas chromatography (GC) analysis
on a Restek Rtx-200 capillary column (60 m × 0.53 mm). Endotoxin level was tested using the LAL
test on the Endosafe-PTS device (Charles River Laboratories, Charleston, SC, USA). After decay of
radioactivity, post-release sterility tests were performed by incubation of the final product solution with
culture media for 14 days. The residual K2.2.2 test was done by visually comparing the spotted sample of
product solution with a standard solution of K2.2.2 on the same TLC plate after development and iodine
staining. Radionuclide identity was confirmed by measuring the half-life of [18F]5. Chemical purity,
radiochemical purity, and specific activity of [18F]5 were determined by HPLC analysis of the final
product solution using the conditions described above. The identity of the labeled compound [18F]5
was confirmed by co-injection of the product solution with the reference standard 5. Stability tests for
[18F]5 from both manual and automated radiosynthesis methods were performed at 2, 4, and 6 h after
the end of synthesis by checking the radiochemical purity using the same analytical HPLC conditions.
4.4. Animal Preparation and Surgery
A healthy beagle dog (11 kg) was sedated with propofol (7.5 mg/kg) via intravenous injection
in the foreleg cephalic vein, and then intubated for mechanical ventilation (Veturi; Cardiopulmonary
Corp., Milford, CT, USA) and anesthesia maintenance. Anesthesia was maintained with 1%–3%
isoflurane, 65% nitrous oxide, and 35% oxygen. The level of anesthesia was determined by monitoring
heart rate, blink reflex and jaw tone. Blood gases, electrolytes (VetStat Electrolyte and Blood Gas
Analyzer, IDEXX Laboratories Inc., Westbrook, ME, USA) and hematocrit were serially measured
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throughout the study and ventilator settings were adjusted accordingly to maintain physiological
conditions. Cardiac rhythm and rate (ECG), oxygen saturation (pulse oximeter), and body temperature
(rectal temperature probe) were monitored via a Phillips InteliVue MP50 monitor. A small femoral
cut-down (4 cm) was performed and a 6F introducer sheath was placed in the right femoral artery to
monitor pressure.
4.5. Animal PET/CT Imaging
The dog was placed feet first in a lateral decubitus position for imaging on a Siemens mCT
PET/CT scanner. ECG leads and a respiratory gating belt were placed for cardiac and respiratory
motion corrections, respectively. Prior to the PET scan, a non-contrast CT scan (120 kV, 11 mAs, 2.0 mm
slices) was performed during temporary detachment from the ventilation to limit respiratory motion
artifact. Following the CT scan, 0.185 GBq of [18F]DHMT was injected via the femoral vein and a 2 h
dynamic PET scan was performed.
All animal experiment protocols were approved by the Institutional Animal Care and Use
Committees at the Yale University School of Medicine (protocol: 2014-11623), according to the guiding
principles of the American Physiological Society on research animal use.
5. Conclusions
We reported an optimized and automated radiosynthesis of [18F]DHMT for large-scale production.
This study is the first demonstration to produce 2-[18F]fluoroethyl azide with an automated module,
which can be used to produce a variety of other PET tracers through click chemistry. The production
process for [18F]DHMT yielded the product in reliably high radiochemical purity and quality suitable
for human use. PET studies demonstrated the feasibility of using [18F]DHMT for imaging of the heart
in a canine model.
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